MA48464A - Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques - Google Patents
Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiquesInfo
- Publication number
- MA48464A MA48464A MA048464A MA48464A MA48464A MA 48464 A MA48464 A MA 48464A MA 048464 A MA048464 A MA 048464A MA 48464 A MA48464 A MA 48464A MA 48464 A MA48464 A MA 48464A
- Authority
- MA
- Morocco
- Prior art keywords
- acetylated
- viscosity
- reducing
- therapeutic polypeptides
- viscous compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492020P | 2017-04-28 | 2017-04-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48464A true MA48464A (fr) | 2020-03-04 |
Family
ID=62165708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048464A MA48464A (fr) | 2017-04-28 | 2018-04-27 | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12103979B2 (fr) |
| EP (1) | EP3615069B1 (fr) |
| AU (1) | AU2018258676B2 (fr) |
| CA (1) | CA3279830A1 (fr) |
| ES (1) | ES3036143T3 (fr) |
| MA (1) | MA48464A (fr) |
| WO (1) | WO2018201064A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021019612A2 (pt) * | 2019-04-01 | 2021-11-30 | Genentech Inc | Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa |
| US12599669B2 (en) | 2019-04-23 | 2026-04-14 | Amgen Inc. | Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| CN115996748A (zh) * | 2020-05-29 | 2023-04-21 | 奇努克医疗公司 | 用APRIL结合抗体治疗IgA肾病的方法 |
| WO2022092183A1 (fr) * | 2020-10-30 | 2022-05-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Composition pharmaceutique |
| AU2021404495A1 (en) * | 2020-12-17 | 2023-07-27 | Astrazeneca Ab | Anti-il5r antibody formulations |
| KR20230152062A (ko) * | 2021-03-03 | 2023-11-02 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항tslp 항체를 포함하는 의약 조성물 |
| AU2022325870A1 (en) * | 2021-08-12 | 2024-02-08 | Amgen Inc. | Antibody formulations |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1690934A3 (fr) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Génération d'anticorps xenogéniques |
| US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| IL160358A0 (en) | 2001-08-23 | 2004-07-25 | Genmab As | Human antibodies specific for interleukin 15 (il-15) |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| WO2008154014A2 (fr) | 2007-06-11 | 2008-12-18 | Amgen Inc. | Methode de culture de cellules mammiferes servant a ameliorer la production de proteines recombinees |
| JP2010530233A (ja) | 2007-06-20 | 2010-09-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | アレルギー疾患を処置する方法および組成物 |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
| KR20130060227A (ko) * | 2010-05-03 | 2013-06-07 | 제넨테크, 인크. | 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법 |
| WO2015196091A1 (fr) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Composés excipient réduisant la viscosité pour formulations à base de protéines |
| AU2015289874A1 (en) * | 2014-07-14 | 2017-02-02 | Amgen Inc. | Crystalline antibody formulations |
| AU2015335743B2 (en) * | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
-
2018
- 2018-04-27 MA MA048464A patent/MA48464A/fr unknown
- 2018-04-27 US US16/607,673 patent/US12103979B2/en active Active
- 2018-04-27 AU AU2018258676A patent/AU2018258676B2/en active Active
- 2018-04-27 EP EP18724732.5A patent/EP3615069B1/fr active Active
- 2018-04-27 CA CA3279830A patent/CA3279830A1/en active Pending
- 2018-04-27 ES ES18724732T patent/ES3036143T3/es active Active
- 2018-04-27 WO PCT/US2018/029981 patent/WO2018201064A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018258676A1 (en) | 2019-10-31 |
| EP3615069B1 (fr) | 2025-05-28 |
| CA3059369A1 (fr) | 2018-11-01 |
| US12103979B2 (en) | 2024-10-01 |
| ES3036143T3 (en) | 2025-09-15 |
| AU2018258676B2 (en) | 2024-09-19 |
| WO2018201064A1 (fr) | 2018-11-01 |
| EP3615069A1 (fr) | 2020-03-04 |
| US20200048367A1 (en) | 2020-02-13 |
| CA3279830A1 (en) | 2026-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48464A (fr) | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques | |
| MA51796A (fr) | Procédés et compositions pour l'administration de protéines thérapeutiques | |
| EP3880717A4 (fr) | Compositions et procédés d'administration de polypeptides effecteurs crispr/cas | |
| EP3880688A4 (fr) | Préparations et compositions d'oligosaccharides | |
| PL3717471T3 (pl) | Nowe związki i zawierające je kompozycje farmaceutyczne do leczenia chorób | |
| EP3704239A4 (fr) | Compositions de casz et procédés d'utilisation | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| EP3427601A4 (fr) | Composition de sirop contenant de l'allulose et aliment la contenant | |
| EP3858941A4 (fr) | Modificateur de fluidité, composition le contenant, et produit durci de ladite composition | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| EP3412660A4 (fr) | Dérivé de sulfonamide et composition pharmaceutique le contenant | |
| EP3777866A4 (fr) | Composition pharmaceutique et application de cette dernière | |
| EP3413887A4 (fr) | Intermédiaires utilisés dans la synthèse d'éribuline et procédés de synthèse associés | |
| SG11202009574RA (en) | Combinations of osteopontin and 2'-fucosyllactose for use as medicaments | |
| IT201700085412A1 (it) | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare | |
| EP3679863A4 (fr) | Ensemble de seringue de produit d'étanchéité | |
| PL3810128T3 (pl) | Kompozycje do leczenia i/lub zapobiegania chorobom związanym z agregacją białek | |
| EP3648773A4 (fr) | Composés et procédés pour l'administration transmembranaire de molécules | |
| EP3817750A4 (fr) | Compositions d'associations de cannabidiol | |
| EP3645120A4 (fr) | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression | |
| EP3484434A4 (fr) | Mousses d'eau dans l'huile contenant de la bétuline et compositions associées | |
| EP3675858A4 (fr) | Composés et compositions pour l'inhibition de ire1 | |
| EP3542821A4 (fr) | MOLÉCULE INDUISANT LA DÉGRADATION DE p53 ET COMPOSITION PHARMACEUTIQUE | |
| EP3638277A4 (fr) | Compositions et procédés d'inhibition de la bêta-sécrétase | |
| EP3255113C0 (fr) | Adhésif et/ou composition d'étanchéité |